title: Voriconazole therapy in children with cystic fibrosis.
abstract: BACKGROUND
  There is increasing evidence for the efficacy of the antifungal voriconazole, particularly in immunosuppression. We describe our experience of using voriconazole in children with CF.
  
  
  METHODS
  We performed a retrospective case note review of children with CF treated with voriconazole in a single centre over an 18 month period.
  
  
  RESULTS
  A total of 21 children aged 5 to 16 years (median 11.3) received voriconazole for between 1 and 50 (22) weeks. Voriconazole was used as monotherapy in 2 children with recurrent allergic bronchopulmonary aspergillosis (ABPA); significant and sustained improvements in clinical and serological parameters for up to 13 months were observed, without recourse to oral steroids. Voriconazole was used in combination with an immunomodulatory agent in a further 11 children with ABPA, with significant improvement in pulmonary function and serology. 8 children without ABPA but who had recurrent Aspergillus fumigatus isolates and increased symptoms also received voriconazole; this group did not improve with treatment. Adverse effects occurred in 7 children (33%: photosensitivity reaction 3, nausea 2, rise in hepatic enzymes 1, hair loss 1).
  
  
  CONCLUSIONS
  Voriconazole may be a useful adjunctive therapy for ABPA in CF. Voriconazole monotherapy appears to be an alternative treatment strategy when oral corticosteroids may not be suitable.
authors.affiliation: Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK. t.hilliard@imperial.ac.uk
authors.forename: Tom
authors.initials: T
authors.lastname: Hilliard
authors.forename: Siân
authors.initials: S
authors.lastname: Edwards
authors.forename: Roger
authors.initials: R
authors.lastname: Buchdahl
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Francis
authors.forename: Mark
authors.initials: M
authors.lastname: Rosenthal
authors.forename: Ian
authors.initials: I
authors.lastname: Balfour-Lynn
authors.forename: Andrew
authors.initials: A
authors.lastname: Bush
authors.forename: Jane
authors.initials: J
authors.lastname: Davies
mesh_terms: D000293:Adolescent; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D001232:Aspergillus fumigatus / Q000302:isolation & purification; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000382:microbiology*; D005260:Female; D006801:Humans; D008172:Lung Diseases, Fungal / Q000188:drug therapy*; D008297:Male; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D013183:Sputum / Q000382:microbiology; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D065819:Voriconazole
chemical_list: D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole